Abstracts tagged "Clinical research"

Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
Abstract Number: 259 • 2014 ACR/ARHP Annual Meeting
Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System
Esi M. Morgan DeWitt¹, Kimberly Barnett², Wen-Hung Chen³, Jennifer Farrell⁴, Dennis Revicki⁵, Adam Carle⁶, Karon Cook⁷, Kenneth Goldschneider⁸, Carlton Dampier⁹, David D. Sherry¹⁰ and Susmita Kashikar-Zuck², ¹Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Evidera, Bethesda, MD, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Outcomes Research, Evidera, Bethesda, MD, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Center for Patient-Centered Outcomes - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, ¹⁰Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose The NIH Patient Reported Outcomes Measurement Information System (PROMIS) has created publicly available patient reported outcomes measures in several domains of physical, social and…
Abstract Number: L15 • 2014 ACR/ARHP Annual Meeting
Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)
Ivan Foeldvari¹, Gerd Horneff², Kirsten Minden³, Ralf Trauzeddel⁴, J B. Kuemmerle-Deschner⁵, Klaus Tenbrock⁶, Gerd Ganser⁷ and Hans-Iko Huppertz⁸, ¹Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ²Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ³Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ⁴Pediatrics, Helios Clinics, Berlin, Germany, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁶University Aachen, Aachen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁸Kinderklinik, Krinikum Bremen-Mitte, Bremen, Germany
Background/Purpose: Enthesitis related arthritis (ERA) is a Juvenile Idiopathic Arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended…
Abstract Number: 2230 • 2014 ACR/ARHP Annual Meeting
Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Asger Bihlet³, Peter Alexandersen⁴, Inger Byrjalsen³, Jeppe Andersen³, Bente J. Riis³ and Claus Christiansen³, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Center for Clinical and Basic Research, Vejle, Denmark
Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a…
Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Philip J. Mease¹, Roy Fleischmann², Owen Davies³, Tommi Nurminen⁴ and Désirée van der Heijde⁵, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting
The Biosimilar Landscape: A Systematic Review of Its Current Status
Niti Goel^1,2 and Kamali Chance³, ¹Rheumatology Center of Excellence, Quintiles, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Global Biosimilars Unit, Quintiles, Durham, NC
Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
Abstract Number: 1436 • 2014 ACR/ARHP Annual Meeting
Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil
Harriet Morf¹, Olga Malysheva², G da Rocha³, Anna Beatriz Vargas³ and Christoph G. Baerwald², ¹Department of Internal Medicine, University Hospital, Leipzig, Germany, ²Rheumatology, University Hospital, Leipzig, Germany, ³Ambulatório de reumatologia da Policlínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose Rheumatoid Arthritis (RA) can be associated with psychological disorders and especially depression. About 13 – 20 % of patients have clinical significant depression. It…
Abstract Number: 2286 • 2013 ACR/ARHP Annual Meeting
Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients
Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha⁴, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²PsAID taskforce, EULAR, Zurich, Switzerland, ³2nd Department of Medicine, Krankenhaus Lainz, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Patient reported outcomes (PRO) represent an important part of outcomes assessment in rheumatoid arthritis (RA) patients. The Patient Global Assessment (PGA) is an essential…
Abstract Number: 2050 • 2013 ACR/ARHP Annual Meeting
Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer. A Prospective Study
Daniel Wendling¹, Helene Letho-Gyselinck¹, Xavier Guillot², Clément Prati³ and Xavier Pivot⁴, ¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ²Department of Rheumatology, CHRU Besançon, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁴Oncology, CHRU Besançon, Besançon, France
Background/Purpose: Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these…
Abstract Number: 1925 • 2013 ACR/ARHP Annual Meeting
Patient Satisfaction with an Associate Teaching Hospital Clinical Trial Unit In North-East London
Genevieve Casey¹, Carey Tierney², Hasan Tahir³, Simon Donnelly³ and Judith Bubbear³, ¹Barts and the London Medical School, London, United Kingdom, ²Whipps Cross Clinical Research Unit, Barts Health NHS Trust, London, United Kingdom, ³Rheumatology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Compared to patient satisfaction with general medical care little is known about patient satisfaction within clinical trials. Clinical trials are a time and resource…
Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting
Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper⁴, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany
Background/Purpose: < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…
Abstract Number: 1386 • 2013 ACR/ARHP Annual Meeting
Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis
Tatsuhiro Yamamoto, Mai Kawazoe, Emiko Shindo, Natsuki Fujio, Kotaro Shikano, Kanako Kitahara, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Kaichi Kaneko, Natsuko Kusunoki, Yoshie Kusunoki, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anchor drug for treatment of rheumatoid arthritis (RA). Appropriate effective and/or tolerable doses of weekly pulse MTX therapy vary widely…
Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Masahiro Tada¹, Tatsuya Koike², Akihiro Tamori³, Tadashi Okano¹, Yuko Sugioka¹, Kenji Mamoto¹, Kentaro Inui⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Adrian Levitsky¹, Kristina Forslind^2,3 and Ronald F. van Vollenhoven⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund, Sweden, ³Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden
Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…
Abstract Number: 1030 • 2013 ACR/ARHP Annual Meeting
Readability of Participant Information and Consent Forms for Rheumatology Clinical Trial Participants
Stephen Hall¹, Gail Grant² and Christina Meyer², ¹Melbourne Rheumatology, Melbourne, Australia, ²emeritus research, melbourne, Australia
Background/Purpose: To determine the readability of written information (Participant Information and Consent Forms [PICS]) provided to clinical trial participants prior to enrolment into a clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].